Overview

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Status:
Not yet recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

This phase I trial tests the safety, side effects, and best dose of a new of liposomal doxorubicin and peposertib in treating patients with sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Chemotherapy drugs, such as liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving liposomal doxorubicin and peposertib may shrink or stabilize sarcoma.

Phase:

Phase 1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Doxorubicin
Liposomal doxorubicin
Peposertib